RT Journal Article
SR Electronic
T1 Same-Day Simultaneous Diagnosis of Bacterial and Fungal Infections in Clinical Practice by Nanopore Targeted Sequencing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.08.20057604
DO 10.1101/2020.04.08.20057604
A1 Wang, Ming
A1 Fu, Aisi
A1 Hu, Ben
A1 Shen, Gaigai
A1 Liu, Ran
A1 Zhao, Wanxu
A1 Jiang, Shupeng
A1 Cai, Xuan
A1 Li, Congrong
A1 Li, Juan
A1 Wu, Qing
A1 Feng, Kai
A1 Gu, Jiashuang
A1 Chen, Jia
A1 Shu, Mingyue
A1 Zhang, Binghong
A1 Deng, Zixin
A1 Yu, Lilei
A1 Li, Yan
A1 Liu, Tiangang
YR 2020
UL http://medrxiv.org/content/early/2020/04/11/2020.04.08.20057604.abstract
AB BACKGROUND As approximately 19% of global deaths are attributable to infectious diseases, early diagnosis of infection is very important to reduce mortality. Traditional infection detection strategies have limited sensitivity, detection range, and turnaround times; a detection technology that can simultaneously detect bacterial and fungal infections within 24 h is urgently need in clinical settings.METHODS We developed nanopore targeted sequencing (NTS) for same-day simultaneous Diagnosis of fungal and bacterial infections. NTS was developed by amplification of 16s rRNA gene (for bacteria), IST1/2 gene (for fungal), and rpoB (for Mycobacterium spp.) using multiple primers, and sequenced by a real-time nanopore sequencing platform. An in-house bioinformatic analyze pipeline was used to diagnose the infectious pathogens by mapping the sequencing results with the constructed databases.RESULTS Comparison of 1312 specimens from 1257 patients using NTS and culture method; NTS detected pathogens in 58.71% of specimens from patients, compared to 22.09% detected using the culture method. NTS showed significantly higher sensitivity than culture methods for many pathogens. Importantly, a turnaround time of <24 h for all specimens, and a pre-report within 6 h in emergency cases was possible in clinical practice. Modification of antibiotic therapy and maintenance of original anti-infection regimens in 51.52% (17/33) and 36.36% (12/33) of patients was in accordance with NTS results, and quantitative monitoring of clinical treatment effects was evaluated in four patients by continuous NTS tests.CONCLUSIONS Application of NTS in clinically detected pathogens can improve targeted antibiotic treatment and therapeutic monitoring.Competing Interest StatementWuhan Dgensee Clinical Laboratory Co., Ltd applied patents based on this novel technology.Funding StatementWuhan Dgensee Clinical Laboratory Co., Ltd supporting this research.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data, models, and code generated or used during the study appear in the submitted article.NTSnanopore targeted sequencingITS1/2fungal internal transcribed spacers 1 and 2ATCCthe American Type Culture CollectionMTBMycobacterium tuberculosisBALFbronchoalveolar lavage fluidCFUcolony-forming unitsRPMaligned reads of per million sequence readsCSFcerebrospinal fluidNTMNontuberculous mycobacteriaPPVpositive predicted valueNPVnegative predicted valuesOPopportunistic pathogensCOcommensal bacteria/fungi